


Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-497E9229-A17D-4947-95B5-595C5101B84B\_4\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M68990\\_04\\_01](https://doi.org/10.31003/USPNF_M68990_04_01)  
 DOI Ref: evj9m

© 2025 USPC  
 Do not distribute

## Prilocaine Hydrochloride



$C_{13}H_{20}N_2O \cdot HCl$  256.77

Propanamide, *N*-(2-methylphenyl)-2-(propylamino)-, monohydrochloride;

2-(Propylamino)-*o*-propionotoluidide monohydrochloride CAS RN<sup>®</sup>: 1786-81-8; UNII: MJW015BAPH.

### DEFINITION

Prilocaine Hydrochloride contains NLT 98.0% and NMT 102.0% of prilocaine hydrochloride ( $C_{13}H_{20}N_2O \cdot HCl$ ), calculated on the dried basis.

### IDENTIFICATION

**Change to read:**

- **A.** [▲SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K▲](#) (CN 1-MAY-2020)
- **B.** [IDENTIFICATION TESTS—GENERAL, Chloride\(191\)](#)

**Analysis:** Dissolve 100 mg in 3 mL of water, render the solution alkaline with 6 N ammonium hydroxide, and filter.

**Acceptance criteria:** The filtrate meets the requirements.

- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Buffer:** 0.18 g/L of monobasic sodium phosphate and 2.89 g/L of dibasic sodium phosphate dihydrate in water

**Mobile phase:** Acetonitrile and *Buffer* (26:74)

**System suitability solution:** 3 µg/mL each of [USP Prilocaine Hydrochloride RS](#) and [USP Prilocaine Related Compound B RS](#) in *Mobile phase*

**Standard solution:** 0.3 mg/mL of [USP Prilocaine Hydrochloride RS](#) in *Mobile phase*

**Sample solution:** 0.3 mg/mL of Prilocaine Hydrochloride in *Mobile phase*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 240 nm

**Column:** 4.6-mm × 15-cm; 5-µm packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

#### Suitability requirements

**Resolution:** NLT 3.0 between prilocaine and prilocaine related compound B, *System suitability solution*

**Tailing factor:** NMT 1.5, *Standard solution*

**Relative standard deviation:** NMT 0.73, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of prilocaine hydrochloride ( $C_{13}H_{20}N_2O \cdot HCl$ ) in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of prilocaine from the *Sample solution*

$r_S$  = peak response of prilocaine from the *Standard solution*

$C_S$  = concentration of [USP Prilocaine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

#### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

#### • ORGANIC IMPURITIES

**Buffer, Mobile phase, System suitability solution, and Chromatographic system:** Proceed as directed in the Assay.

**Standard solution 1:** 3 µg/mL of [USP Prilocaine Hydrochloride RS](#) in *Mobile phase*

**Standard solution 2:** 0.4 µg/mL of [USP Prilocaine Related Compound A RS](#) in *Mobile phase*

**Sample solution:** 3 mg/mL of Prilocaine Hydrochloride in *Mobile phase*

#### System suitability

**Samples:** *System suitability solution* and *Standard solution 2*

[NOTE—See [Table 1](#) for the relative retention times.]

#### Suitability requirements

**Resolution:** NLT 3.0 between prilocaine and prilocaine related compound B, *System suitability solution*

**Signal-to-noise ratio:** NLT 10 for prilocaine related compound A, *Standard solution 2*

#### Analysis

**Samples:** *Standard solution 1*, *Standard solution 2*, and *Sample solution*

Calculate the percentage of prilocaine related compound A in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of prilocaine related compound A from the *Sample solution*

$r_S$  = peak response of prilocaine related compound A from *Standard solution 2*

$C_S$  = concentration of [USP Prilocaine Related Compound A RS](#) in *Standard solution 2* (mg/mL)

$C_U$  = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any unspecified impurity from the *Sample solution*

$r_S$  = peak response of prilocaine from *Standard solution 1*

$C_S$  = concentration of [USP Prilocaine Hydrochloride RS](#) in *Standard solution 1* (mg/mL)

$C_U$  = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** See [Table 1](#). The reporting level for impurities is 0.05%.

**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Prilocaine related compound A	0.3	0.01
Prilocaine	1.0	—

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Prilocaine related compound B	1.2	—
Any individual unspecified impurity	—	0.10
Total impurities	—	0.2

#### SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

**Analysis:** Dry a sample at 105° for 4 h.

**Acceptance criteria:** NMT 0.3%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at room temperature.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Prilocaine Hydrochloride RS](#)

[USP Prilocaine Related Compound A RS](#)

o-Toluidine hydrochloride.

$C_7H_9N \cdot HCl$  143.62

[USP Prilocaine Related Compound B RS](#)

(RS)-N-(4-Methylphenyl)-2-(propylamino)propanamide.

$C_{13}H_{20}N_2O$  220.31

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PRILOCAINE HYDROCHLORIDE	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(6)

**Current DocID:** GUID-497E9229-A17D-4947-95B5-595C5101B84B\_4\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M68990\\_04\\_01](https://doi.org/10.31003/USPNF_M68990_04_01)

**DOI ref:** [evj9m](#)